文献速递胰腺与胆道疾病消化内镜

商业保险人群中经内镜逆行胰胆管造影术后胰腺炎的负担与费用

Burden and cost of post-endoscopic retrograde cholangiopancreatography pancreatitis among commercially insured people undergoing endoscopic retrograde cholangiopancreatography.
PubMed 文献 · Gastrointest Endosc · 2025-03-20

基于美国商业理赔数据,2019至2021年共27482例患者接受42212例次ERCP,5.7%发生术后胰腺炎。术后胰腺炎患者30天调整后平均直接费用为38569美元,无胰腺炎者为30103美元,差值8483美元。

要点

  • 27482例患者中ERCP术后胰腺炎发生率为5.7%。
  • ≤17岁组发生术后胰腺炎的比值比最高,OR为1.53(95%CI 1.06-2.21)。
  • 术后胰腺炎患者30天调整后平均直接费用较无胰腺炎者高8483美元。

核心结论

  • ERCP术后胰腺炎相对不常见,发生率约5%至6%,但造成显著经济负担。

研究设计与样本

  • 使用Merative MarketScan商业理赔数据,识别2019至2021年住院和门诊ERCP,纳入27482例患者共42212例次ERCP。
  • 主要结局为ERCP后30天内发生术后胰腺炎,采用多变量回归识别相关因素并估算调整后费用。

主要发现

  • 27482例患者中,5.7%观察到ERCP术后胰腺炎。
  • 多变量分析中,≤17岁年龄组接受ERCP者发生术后胰腺炎的比值比最高,OR为1.53(95%CI 1.06-2.21)。
  • 有和无术后胰腺炎者30天调整后平均直接费用分别为38569美元和30103美元,差值为8483美元。
  • 术后胰腺炎的人群层面费用在美国报告的不同发生率和年ERCP量估算下范围为85833757至432648810美元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: ERCP is the primary therapeutic procedure for pancreaticobiliary diseases. Post-ERCP pancreatitis can occur in up to 10% to 15% of cases; however, very little data describe the incidence and financial burden of post-ERCP pancreatitis in a nationally representative sample in the United States. In this study, we characterized the 30-day incidence of post-ERCP pancreatitis, identified patient- and procedure-related factors associated with post-ERCP pancreatitis, and described 30-day direct and out-of-pocket (OOP) costs among patients with post-ERCP pancreatitis. METHODS: We used the Merative MarketScan commercial claims data to identify inpatient and outpatient ERCPs occurring from 2019 to 2021. The primary outcome was the development of post-ERCP pancreatitis within 30 days of an ERCP. The main measure of financial burden was the total direct and OOP costs of the index ERCP and all encounters within 30 days after the index ERCP. We used multivariable regression to identify factors and estimate adjusted costs of post-ERCP pancreatitis. RESULTS: Among 27,482 patients who underwent 42,212 ERCPs during the study period, post-ERCP pancreatitis was observed in 5.7% of patients. In multivariable analysis, the highest odds of post-ERCP pancreatitis was observed among the youngest age group (≤17 years) undergoing ERCP (odds ratio, 1.53; 95% CI, 1.06-2.21). The 30-day adjusted mean direct costs among persons with and without post-ERCP pancreatitis were $38,569 and $30,103, respectively (difference, $8483). The population-level cost of post-ERCP pancreatitis ranged from $85,833,757 to $432,648,810 across a range of reported estimates for post-ERCP pancreatitis and annual ERCP volume in the United States. CONCLUSIONS: Post-ERCP pancreatitis is relatively uncommon, occurring in 5% to 6% of individuals, but results in substantial financial burden.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Tavakkoli A, Kapinos KA, Elmunzer BJ, et al. Burden and cost of post-endoscopic retrograde cholangiopancreatography pancreatitis among commercially insured people undergoing endoscopic retrograde cholangiopancreatography. Gastrointest Endosc. 2025. PMID: 40120865. doi:10.1016/j.gie.2025.03.639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。